Effectiveness Of Hematopoietic Stem Cell Transplantation For Hematological Disorders In125Patients

Objective To evaluate the clinical effectiveness and complications ofhematopoietic stem cell transplantation (HSCT) in the treatment ofhematological disorders.Methods The clinical data from125patients with hematologicdiseases who received PBSCT from Jan2004to Oct2011in our hospitalwere retrospectively analyzed. Among the125patients, median age is43year,47(21with acute leukemia,18with chronic myeloid leukemia,5withof severe aplastic anemia I type,1with lymphoma and2with of MDS)were treated with allogenic hematopoietic stem cell transplantation(Allo-HSCT); other78patients (43with lymphoma,18with acuteleukemia, and17with multiple myeloma) were treated with autologoushematopoietic stem cell transplantation (Auto-HSCT).Results Hemapoietic reconstruction was successful in patients. Theaverage time was11.5d for neutrophil reconstruction (≧0.5×109/L)and14.8d for platelet reconstruction (≧20×109/L). The incidence of acute andchronic graft-versus-host-disease (aGVHD and (cGVHD) in allo-HSCTwas12.8%and23.4%respectively.Median follow-up time was11months. The incidence of disease relapse was26.9%in auto-HSCT group and10.6%in Allo-HSCT group.The total relapse rate was20.8%. TheKaplan-Meier curve of the overall survival (OS),disease free survival(DFS) showed no significant difference between auto-HSCT andallo-HSCT.Conclusions HSCT can provide rapid hematopoietic reconstitution. Itis a better choice for the cure of malignant hematologic diseases.